Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Non-Current Debt (2019 - 2025)

Puma Biotechnology (PBYI) has disclosed Non-Current Debt for 7 consecutive years, with $10.9 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Non-Current Debt fell 75.15% year-over-year to $10.9 million, compared with a TTM value of $10.9 million through Jun 2025, down 75.15%, and an annual FY2024 reading of $21.7 million, down 66.92% over the prior year.
  • Non-Current Debt was $10.9 million for Q2 2025 at Puma Biotechnology, up from $10.6 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $98.6 million in Q1 2023 and bottomed at $10.6 million in Q1 2025.
  • Average Non-Current Debt over 5 years is $68.5 million, with a median of $76.5 million recorded in 2021.
  • The sharpest move saw Non-Current Debt surged 42.17% in 2022, then tumbled 80.53% in 2025.
  • Year by year, Non-Current Debt stood at $97.1 million in 2021, then increased by 1.25% to $98.3 million in 2022, then tumbled by 33.21% to $65.7 million in 2023, then tumbled by 66.92% to $21.7 million in 2024, then tumbled by 49.96% to $10.9 million in 2025.
  • Business Quant data shows Non-Current Debt for PBYI at $10.9 million in Q2 2025, $10.6 million in Q1 2025, and $21.7 million in Q4 2024.